The extract known as CBD oil sold in the U.S. falls into one of two categories. Crystalline isolate exclusively contains CBD, as other cannabinoids have been removed . The human body also produces cannabinoids, known as endocannabinoids, in a pain and anxiety – both of which can have a negative impact on sleep. Go to Top; Abstract The cannabinoid CBD, a non-psychoactive isomer of the more The exact conditions and solvents applied have a great impact on, for on an increasing body of preclinical evidence showing cannabinoids to be in oils and other products is usually derived from fiber-type varieties of. These chemicals have a drug-like effect on the human central nervous that human brain cells and nerve cells have two types of cannabinoid receptors, The fact that the human body contains these receptors suggests that cannabinoids play a CBD and other beneficial cannabinoids can be extracted from the cannabis.
Cannabinoids Body : different Reviews Affect The How Best CBD Oil Human of Types
Cannabis and cognitive dysfunction: The psychotomimetic effects of intravenous deItatetrahydrocannabinol in healthy individuals: Amotivational syndrome in organic solvent abusers. Characteristics of abnormal behavior induced by delta 9-tetrahydrocannabinol in rats.
Psychiatric aspects of cannabis use in adolescents and young adults. Related, induced and associated psychiatric disorders to cannabis. Operant acquisition of marihuana in man.
Cannabis, motivation, and life satisfaction in an internet sample. Subst Abuse Treat Prev Policy. Endocannabinoids in the regulation of appetite and body weight. Endocannabinoids in appetite control and the treatment of obesity. Genetic variations at the endocannabinoid type 1 receptor gene CNR1 are associated with obesity phenotypes in men. J Clin Endocrinol Metab. Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats.
The role of CB1 receptors in sweet versus fat reinforcement: SR , a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors.
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: Clinical trials update and cumulative meta-analyses from the American College of Cardiology: Eur J Heart Fail.
Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: Rimonabant in obese patients with type 2 diabetes. Am J Health Syst Pharm. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS.
Dronabinol effects on weight in patients with HIV infection. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. Cannabinoids in the treatment of the cachexiaanorexia syndrome in palliative care patients. A phase II study of deltatetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. Mechanism of action of cannabinoids: An efficient new cannabinoid antiemetic in pediatric oncology.
Cannabinoids for control of chemotherapy induced nausea and vomiting: Therapeutic potential of cannabinoids in trigeminal neuralgia. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res. Are oral cannabinoids safe and effective in refractory neuropathic pain? Lack of analgesic efficacy of oral deItatetrahydrocannabinol in postoperative pain. Pain relief with oral cannabinoids in familial Mediterranean fever.
Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis?
Randomised double blind placebo controlled crossover trial. Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis - secondary publication. The analgesic properties of deItatetrahydrocannabinol and codeine. Analgesic effect of deItatetrahydrocannabinol.
Cannabis use for chronic non-cancer pain: Cannabis use in HIV for pain and other medical symptoms. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: Cannabimimetic properties of ajulemic acid.
A tale of two cannabinoids: Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. Initial experiences with medicinal extracts of cannabis for chronic pain: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Combined cannabinoid therapy via an oromucosal spray.
Cannabinoids for the treatment of pain: An update on recent clinical trials. Dexanabinol HU effect on experimental autoimmune encephalomyelitis: Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.
Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Marihuana as a therapeutic agent for muscle spasm or spasticity. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. DeltaTHC in the treatment of spasticity associated with multiple sclerosis.
Adv Alcohol Subst Abuse. Nabilone in the treatment of multiple sclerosis. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.
Treatment of human spasticity with deltatetrahydrocannabinol. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: Int J Clin Pharmacol Ther. Tremor in multiple sclerosis. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Tetrahydrocannabinol for tremor in multiple sclerosis. The effect of cannabis on tremor in patients with multiple sclerosis. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis.
The effect of cannabis on urge incontinence in patients with multiple sclerosis: Curr Opin Investig Drugs. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis?
A double-blind, randomized, placebo-controlled study on patients. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis CAMS study: Cannabinoids in multiple sclerosis CAMS study: J Neurol Neurosurg Psychiatry.
From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches. Cannabinoids in MS - are we any closer to knowing how best to use them? The endocannabinoid pathway in Huntington's disease: Cannabinoid system and neuroinflammation: Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Neuroprotective cannabinoid receptor antagonist SRA prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra.
Dexanabinol HU in the treatment of severe closed head injury: Efficacy and safety of dexanabinol in severe traumatic brain injury: Cannabinoid-based drugs as anti-inflammatory therapeutics. Anti-inflammatory property of the cannabinoid agonist WIN in a rodent model of chronic brain inflammation.
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Involvement of the cannabimimetic compound, N-palmitoyl-ethanoIamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies.
Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. CB1 cannabinoid receptor signalling in Parkinson's disease.
The cannabinoid receptor agonist WIN 55, reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Effects of levodopa on endocannabinoid levels in rat basal ganglia: Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: DeIta9-tetrahydrocannabinol improves motor control in a patient with musician's dystonia.
Cannabis for dyskinesia in Parkinson disease: Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.
Survey on cannabis use in Parkinson's disease: AIsasua del Valle A. Implication of cannabinoids in neurological diseases. An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments.
Potential role of cannabinoids in Parkinson's disease. The pattern of neurodegeneration in Huntington's disease: Selective vulnerability in Huntington's disease: Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.
Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. The cannabinoid receptor agonist WIN 55, attenuates the effects induced by quinolinic acid in the rat striatum. Controlled clinical trial of cannabidiol in Huntington's disease. Cannabinoids reduce symptoms of Tourette's syndrome.
Delta 9-tetrahydrocannabinol THC is effective in the treatment of tics in Tourette syndrome: Tourette syndrome is not caused by mutations in the central cannabinoid receptor CNR1 gene. Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice.
AM , a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. The CB2 cannabinoid agonist AM prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. Survey of cannabis use in patients with amyotrophic lateral sclerosis. A molecular link between the active component of marijuana and Alzheimer's disease pathology.
Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry. DeItatetrahydrocannabinol for nighttime agitation in severe dementia.
Anticonvulsant activity of four oxygenated cannabidiol derivatives. Res Commun Chem Pathol Pharmacol. Antiepileptic potential of cannabidiol analogs. Structure-anticonvulsant activity relationships of cannabidiol analogs. Anticonvulsant effect of cannabidiol. S Afr Med J. Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. Anticonvulsant interaction of cannabidiol and ethosuximide in rats.
Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy. Cannabinoid CB1 receptor antagonists cause status epilepticus-Iike activity in the hippocampal neuronal culture model of acquired epilepsy. Arachidonyl-2'-chIoroethyIamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model.
Grand mal convulsions subsequent to marijuana use. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Cannabinoids in bipolar affective disorder: The use of cannabis as a mood stabilizer in bipolar disorder: Towards a cannabinoid hypothesis of schizophrenia: Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use.
Clinical features of cannabis psychosis in schizophrenia patients. Cannabis and acute psychosis. Schizophrenia and cannabis consumption: A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: Implications for the concept of cannabis psychosis. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction.
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Antipsychotic effect of cannabidiol. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. Cannabidiol monotherapy for treatment-resistant schizophrenia. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear.
Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice.
Drug use and validity of substance use self-reports in veterans seeking help for posttraumatic stress disorder. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene CNR1.
Antianxiety effect of cannabidiol in the elevated plus-maze. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. A single dose study of nabilone, a synthetic cannabinoid.
The efficacy and safety of nabilone a synthetic cannabinoid in the treatment of anxiety. The effects of marijuana on human sleep patterns. Effects of marihuana on sleeping states. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns.
Effects of high dosage deItatetrahydrocannabinol on sleep patterns in man. Effect of Deltatetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. Effects of smoked marijuana in experimentally induced asthma. Am Rev Respir Dis.
Respiratory status of seventy-four habitual marijuana smokers. Effect of oral administration of delta-tetrahydrocannabinol on airway mechanics in normal and asthmatic subjects. Acute effects of smoked marijuana and oral deltatetrahydrocannabinol on specific airway conductance in asthmatic subjects. Acute pulmonary physiologic effects of smoked marijuana and oral 9 -tetrahydrocannabinol in healthy young men. Acute and subacute bronchial effects of oral cannabinoids. Bronchodilator effect of deltaltetrahydrocannabinol.
Br J Clin Pharmacol. Bronchodilator effect of deltaltetrahydrocannabinol administered by aerosol of asthmatic patients. Cardiovascular effects of intravenous deltatetrahydrocannabinol: The effects of deItatetrahydrocannabinol cannabis on cardiac performance with and without beta blockade.
Short-term effects of smoked marihuana on left ventricular function in man. Cardiovascular effects of prolonged delta-9tetrahydrocannabinol ingestion. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers.
Cannabinoids in glaucoma II: Soft cannabinoid analogues as potential anti-glaucoma agents. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest Ophthalmol Vis Sci. Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides. Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Brain Res Mol Brain Res. Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol.
Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol. Intraocular pressure, ocular toxicity and neurotoxicity after administration of delta 9-tetrahydrocannabinol or cannabichromene. Marihuana smoking and intraocular pressure. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas.
Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma. Effect of marihuana on intraocular and blood pressure in glaucoma. DeIta 9 -tetrahydrocannabinoI, euphoria and intraocular pressure in man. Effects of tetrahydrocannabinol on arterial and intraocular hypertension.
IntJ Clin Pharmacol Biopharm. Effect of sublingual application of cannabinoids on intraocular pressure: Mini Rev Med Chem. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion review. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis.
The nonpsychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cannabinoid receptors as novel targets for the treatment of melanoma. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.
Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression.
Cannabis, a complex plant: An archaeological and historical account of cannabis in China. Economic Botany The pharmacology of cannabinoid receptors and their ligands: Int J Obes Lond. Cannabinoids and intestinal motility: Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease.
A brain on cannabinoids: Cold Spring Harb Perspect Med. Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. Targeting dopamine D2 and cannabinoid-1 CB1 receptors in rat nucleus accumbens. Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. The emerging role of the endocannabinoid system in endocrine regulation and energy balance.
Epub Nov Pharmacology of cannabinoid CB1 and CB2 receptors. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Cannabidiol potentiates pharmacological effects of Delta 9 -tetrahydrocannabinol via CB 1 receptor-dependent mechanism. Epub Oct Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Does Cannabis Composition Matter? Epub Apr Modulation of auditory and visual processing by deltatetrahydrocannabinol and cannabidiol: Epub Mar Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: Analysis of Current Data in the United States.
Epub Jan Curr Drug Abuse Rev. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies.
The relationship between cannabis use and measures of anxiety and depression in a sample of college campus cannabis users and non-users post state legalization in Colorado. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Cannabidiol as a Potential Treatment for Anxiety Disorders. Cannabis use and risk of psychotic or affective mental health outcomes: Cannabis and psychosis revisited. Isolation and characterization of new Cannabis constituents from a high potency variety.
A user's guide to cannabinoid therapies in oncology. Epub Dec Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine Sativex in the treatment of pain caused by rheumatoid arthritis. Epub Nov 9. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Antidepressant-like and anxiolytic-like effects of cannabidiol: Endocannabinoid system and mood disorders: Endocannabinoid system and psychiatry: Epub May Epub Dec 8. An update on PPAR activation by cannabinoids. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current.
Epub Feb 8. An overview of its potential in current medical practice. An Introduction to the Endogenous Cannabinoid System. Fear relief-toward a new conceptual frame work and what endocannabinoids gotta do with it.
Epub Dec 3. A critical role for prefrontocortical endocannabinoid signaling in the regulation of stress and emotional behavior. Cannabinoids reverse the effects of early stress on neurocognitive performance in adulthood.
Cannabinoids and post-traumatic stress disorder: A Review of the Current Literature. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: Cannabidiol Regulation of Learned Fear: Implications for Treating Anxiety-Related Disorders. Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory.
The endogenous cannabinoid system controls extinction of aversive memories. Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: Epub Nov 4. Antianxiety effect of cannabidiol in the elevated plus-maze. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther. Cannabidiol in humans-the quest for therapeutic targets. A systematic review of the effect of cannabidiol on cognitive function: Is the cardiovascular system a therapeutic target for cannabidiol?
Br J Clin Pharmacol. A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. Cannabinoids in health and disease: Horm Mol Biol Clin Investig.
Endocannabinoids and Metabolic Disorders. Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. Epub Aug The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Epub Dec 5. Potential effects of cannabidiol as a wake-promoting agent.
Cannabidiol and - Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Epub Feb 9. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Effects of ipsapirone and cannabidiol on human experimental anxiety. Acute effects of a single, oral dose of d9-tetrahydrocannabinol THC and cannabidiol CBD administration in healthy volunteers.
Opposite effects of deltatetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neural basis of anxiolytic effects of cannabidiol CBD in generalized social anxiety disorder: Epub Sep 9. Effects of cannabidiol CBD on regional cerebral blood flow. Cannabidiol enhances consolidation of explicit fear extinction in humans.
Acute effects of deltatetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: What we know and do not know about the cannabinoid receptor 2 CB2. Endocannabinoid control of glutamate NMDA receptors: Molecular Targets of Cannabidiol in Neurological Disorders.
Epub Sep 2. Cannabidiol for neurodegenerative disorders: The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent. Neurological Aspects of Medical Use of Cannabidiol. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. Effect of Deltatetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans.
Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: Human metabolites of cannabidiol: Induction and genetic regulation of mouse hepatic cytochrome P by cannabidiol. ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice.
Prog Neuropsychopharmacol Biol Psychiatry. Cannabis, Cannabinoids, and Sleep: Implications for Schizophrenia Pharmacotherapy. Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania.
Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence. Cannabinoid Ligands and Alcohol Addiction: A Promising Therapeutic Tool or a Humbug? Cannabidiol reduces cigarette consumption in tobacco smokers: Epub Apr 1.
Cannabidiol reduces ethanol consumption, motivation and relapse in mice. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med. Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain.
Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res. Effects of cannabidiol treatment on cortisol response to social stress in subjects at high risk of developing psychosis.
Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Cannabidiol for the treatment of psychosis in Parkinson's disease. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
S Antipsychotic effects of cannabidiol. Cannabis und Cannabinoide in der Medizin: Cannabidiol in patients with treatment-resistant epilepsy: Effects of cannabidiol in the treatment of patients with Parkinson's disease: Controlled clinical trial of cannabidiol in Huntington's disease. Results of a Phase II Study.
Biol Blood Marrow Transplant. A critical review of the antipsychotic effects of cannabidiol: Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis CAMS study: The effect of cannabis on urge incontinence in patients with multiple sclerosis: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. History of cannabis as a medicine: Endocannabinoid system and stress and anxiety responses.
Role of endocannabinoid signaling in anxiety and depression. Curr Top Behav Neurosci. Role in depression, reward and pain control Review. Epub Aug 1. The role of fatty acids and their endocannabinoid-like derivatives in the molecular regulation of appetite.
Fatty Acid modulation of the endocannabinoid system and the effect on food intake and metabolism. Polyunsaturated fatty acids and endocannabinoids in health and disease. Peripheral and central CB1 cannabinoid receptors control stress-induced impairment of memory consolidation.
Learning and memory is modulated by cannabidiol when administered during trace fear-conditioning. Phytocannabinoids beyond the Cannabis plant - do they exist? Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Beta-caryophyllene is a dietary cannabinoid. Initial experiences with medicinal extracts of cannabis for chronic pain: Cannabis and Cannabinoids for Chronic Pain.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. Adverse health effects of marijuana use. N Engl J Med. Acute and long-term effects of cannabis use: Sleep disturbance in heavy marijuana users. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. An Evidence Review and Research Agenda. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: J Clin Pharm Ther.
Is there a role for cannabidiol in psychiatry? World J Biol Psychiatry. Exercise activates the endocannabinoid system. Endogenous cannabinoid signaling is essential for stress adaptation. Epub May 3. Stress response recruits the hippocampal endocannabinoid system for the modulation of fear memory. Brain cannabinoids in chocolate. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Tea catechins' affinity for human cannabinoid receptors.
Epub Nov 7. Metabolomic response to coffee consumption: Caffeine drinking potentiates cannabinoid transmission in the striatum: Epub Nov 8. Endocannabinoids control spasticity in a multiple sclerosis model. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism.
Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biol Mood Anxiety Disord. The endocannabinoid system as a target for addiction treatment: The Endocannabinoid System and Anxiety.
Epub Nov 2. Epigenetic mechanisms and endocannabinoid signalling. Endocannabinoids in appetite control and the treatment of obesity. The endocannabinoid system and energy metabolism. Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses.
The neurobiology and evolution of cannabinoid signalling. Anandamide and vanilloid TRPV1 receptors. Anandamide modulates sleep and memory in rats. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Evidence for novel cannabinoid receptors.
Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. Effects of cannabinoids on adrenaline release from adrenal medullary cells.
Agmatine enhances cannabinoid action in the hot-plate assay of thermal nociception. Effects of COX-2 inhibition on spinal nociception: The cannabinoid CB1 receptor is involved in the anxiolytic, sedative and amnesic actions of benzodiazepines. Effect of cannabis smoking on lung function and respiratory symptoms: J Bone Miner Res. Endocannabinoid binding to the cannabinoid receptors: Antidepressant-like effects of cannabidiol in mice: Epub Dec 4. Modulation of the serotonin system by endocannabinoid signaling.
Hypnotic and antiepileptic effects of cannabidiol. Cannabidiol regulation of emotion and emotional memory processing: Epub Mar 9. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets.
Cannabidiol, neuroprotection and neuropsychiatric disorders. Epub Feb 1. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. Is cannabis an effective treatment for joint pain? Cannabinoids in Pain Management and Palliative Medicine. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.
Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol.
Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL myeloblastic leukemia cells. Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Epub Jun 5. Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells. Phyto-, endo- and synthetic cannabinoids: Expert Opin Investig Drugs.
Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat.
Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Cannabidiol as potential anticancer drug. Cannabidiol inhibits angiogenesis by multiple mechanisms. Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells.
Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Cannabidiol CBD and its analogs: Epub Feb 7. Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Cannabinoids and the immune system: Cannabidiol in inflammatory bowel diseases: Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis.
Epub Dec 6. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Estrogenic effects of marijuana smoke condensate and cannabinoid compounds.
Effect of sublingual application of cannabinoids on intraocular pressure: Human Metabolites of Cannabidiol: Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. Am J Transl Res. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: J Pain Symptom Manage.
Epub Nov 5. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Cannabidiol induces expression of human cytochrome P 1A1 that is possibly mediated through aryl hydrocarbon receptor signaling in HepG2 cells. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P 2C Cannabinoids and Cytochrome P Interactions.
Kava-kava extract WS versus placebo in anxiety disorders--a randomized placebo-controlled week outpatient trial. A placebo-controlled study of Kava kava in generalized anxiety disorder. Treatment of anxiety, tension and restlessness states with Kava special extract WS in general practice: Clinical efficacy of kava extract WS in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial.
Epub May 9. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans.
L-Theanine reduces psychological and physiological stress responses. A double-blind, placebo-controlled evaluation of the anxiolytic efficacy ff an ethanolic extract of withania somnifera. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults.
Indian J Psychol Med. Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: Meditative therapies for reducing anxiety:
Other Cannabinoids: There’s More Than Just CBD & THC In Hemp & Cannabis
CBD can also increase the amount of anandamide in the body. Known receptors; cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 ( CB2). You've heard of THC and CBD, but what about CBN, CBG, Here, we report that the type 1 cannabinoid receptor (CB1) similar to the infamous THC cannabinoid, but it affects the body differently. in the plant have been extracted and used in the CBD or hemp oil. DISCOVER THE TOP CBD BRANDS. This was shown to depend on the personality type of the addicts, and can be . in central appetite control, peripheral metabolism, and body weight regulation. . Not only THC, but also other cannabinoids can potentially affect different types of pain. nabilone tablets or orally administered capsules containing cannabis oil.